Editorial Policy
GLP-1 Price Guide is an independent editorial pricing publication. Provider rankings are based on publicly available pricing, transparency, provider oversight, pharmacy sourcing, and patient affordability factors — not paid placements.
Editorial Independence
GLP-1 Price Guide maintains editorial independence from the providers and pharmacies we cover. The following principles govern all editorial content:
- No paid placements that influence rankings. Provider rankings are based exclusively on our published v1.0 pricing methodology.
- Transparent affiliate disclosure. If a material relationship exists with any provider mentioned, it is disclosed on the relevant page and in our affiliate disclosure.
- No content removal in exchange for payment. Editorial coverage is not removed because a provider considers it unflattering, provided it is factually accurate.
- Verifiable sources only. Pricing data is sourced from provider's own pages, signup flows, and dated third-party references. We do not invent pricing.
Editorial Team
GLP-1 Price Guide Editorial Team comprises pricing analysts and writers focused on telehealth pricing transparency. We are not licensed medical professionals. We do not provide medical advice. All medical claims are sourced from licensed clinicians, peer-reviewed publications, and FDA documentation.
Review Cadence
- Pricing data: Re-verified the 1st of each month
- Methodology: Reviewed quarterly
- Regulatory content: Reviewed when FDA actions or regulatory changes occur
- Provider profiles: Reviewed quarterly or when material provider changes are reported
Source Hierarchy
Pricing data is collected in this priority order:
- Provider's own published pricing pages (homepage, plans, FAQ, legal/terms)
- Provider's signup flow (checkout pre-payment disclosure)
- Third-party pricing comparisons with date stamps (Forbes Health, GoodRx, Healthline)
- Patient-reported pricing on review platforms (Trustpilot, Reddit) where corroborated by ≥3 independent reports
Corrections
We correct factual errors transparently. See our corrections policy. Pricing corrections are prioritized and processed within 48 hours.
Conflict of Interest Disclosure
GLP-1 Price Guide does not own or operate any compounded GLP-1 telehealth provider. We do not own equity in any provider mentioned in our coverage. Any affiliate or sponsorship relationship is disclosed on the relevant page.
Editorial Boundaries
This publication does not:
- Provide medical advice, diagnosis, or treatment
- Prescribe medication
- Manufacture or compound medication
- Sell GLP-1 treatment
- Operate a pharmacy
- Recommend specific medications for individual patients (this requires a licensed clinician)
Contact
Editorial inquiries, corrections, and source submissions: glponepriceguide@gmail.com
Sources reviewed
- Provider pricing pages (live as of June 1, 2026)
- Provider terms, refund, and support pages
- Third-party pricing comparisons and analyst reports
- FDA — Medications containing semaglutide marketed for type 2 diabetes or weight loss
- FDA — Compounding and the FDA: Questions and Answers
- FDA — Drug Shortages database
- DailyMed (NIH) — Wegovy, Ozempic, Zepbound, Mounjaro prescribing information
- NEJM — STEP-1 (Wilding 2021), SELECT (Lincoff 2023), SURMOUNT-1 (Jastreboff 2022)
- Eli Lilly investor briefings on retatrutide development pipeline (Phase 3 trials)
- State Board of Pharmacy licensure lookups (varies by state)
- Federation of State Medical Boards — FSMB DocInfo physician verification
- LegitScript healthcare merchant directory (where applicable)